A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation. 2006

Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, People's Republic of China.

The reversible S-adenosyl-l-homocysteine hydrolase inhibitor DZ2002 [methyl 4-(adenin-9-yl)-2-hydroxybutanoate] suppresses antigen-induced-specific immune responses, particularly type 1 helper T cell (Th1)-type responses. Experimental autoimmune encephalomyelitis (EAE) is thought to be a Th1 cell-mediated inflammatory demyelinating autoimmune disease model of human multiple sclerosis (MS). In this study, we examined the effects of DZ2002 on active EAE induced by myelin oligodendrocyte glycoprotein (MOG) 35-55 in female C57BL/6 mice. Administration of DZ2002 (50 mg/kg/day i.p.) significantly reduced the incidence and severity of EAE, which was associated with the inhibition of MOG35-55-specific T cell proliferation and Th1-type cytokine production. In vitro studies also demonstrated that DZ2002 inhibited anti-CD3/28-induced naive T cell activation concomitant with the down-regulation of cyclin-dependent kinase (CDK) 4, CDK6, cyclin D3, and the up-regulation or protection of the CDK inhibitor p27. These findings highlight the fact that DZ2002 likely prevents EAE by suppressing T cell activation and suggest its utility in the treatment of MS and other Th1-mediated inflammatory diseases.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated

Related Publications

Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
April 1993, Journal of immunology (Baltimore, Md. : 1950),
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
September 1977, Molecular pharmacology,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
June 1996, Journal of medicinal chemistry,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
April 1993, Journal of medicinal chemistry,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
March 1995, Immunopharmacology,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
March 2010, Acta crystallographica. Section F, Structural biology and crystallization communications,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
June 2004, Journal of inorganic biochemistry,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
May 2005, The Journal of pharmacology and experimental therapeutics,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
January 2018, Frontiers in microbiology,
Yun-Feng Fu, and Yi-Na Zhu, and Jia Ni, and Xiang-Gen Zhong, and Wei Tang, and Yu-Dan Re, and Li-Ping Shi, and Jin Wan, and Yi-Fu Yang, and Chong Yuan, and Fa-Jun Nan, and Brian R Lawson, and Jian-Ping Zuo
June 2003, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!